Immunology Investor Event
Sanofi ambition to address unmet medical needs for
a broad spectrum of AD and Asthma patients
Mild
Moderate-Severe
sanofi
AD
sanofi
Asthma
Inhalers
disease control, but
Topicals
safe and efficacious
noncompliance an issue
Safe Orals
for less severe AD
Topical BTKI
rilzabrutinib
IRAK-4 degrader
rilzabrutinib
Others
AD and
Asthma
Except with respect to Dupixent, all listed agents are investigational and the safety and efficacy has not been evaluated by any regulatory authority
29 Immunology Investor Event
sanofi
Potential for higher efficacy biologics
Injectables
novel MoAs
DUPIXENT
(dupilumab)
amlitelimab (T2 and mixed)
anti-IL-13/OX40L NanobodyⓇ VHH
DUPIXENT
(dupilumab)
amlitelimab (T2 and non-T2)
anti-IL-13/TSLP NanobodyⓇ VHH
anti-IL-13/OX40L NanobodyⓇ VHH
Marketed injectablesView entire presentation